Cargando…
Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
BACKGROUND: Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may be worth exploring in patients who do not benef...
Autores principales: | Cai, Xuan, Fu, Haixia, Zhao, Xiangyu, Lu, Jin, Jiang, Qian, Chang, Yingjun, Huang, Xiaojun, Zhang, Xiaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771238/ https://www.ncbi.nlm.nih.gov/pubmed/36535011 http://dx.doi.org/10.1097/CM9.0000000000002346 |
Ejemplares similares
-
A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
por: Zhu, Qiuhua, et al.
Publicado: (2021) -
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
por: González-Porras, José R., et al.
Publicado: (2019) -
PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023) -
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023) -
Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
por: Erickson-Miller, Connie L, et al.
Publicado: (2009)